Last reviewed · How we verify
Characterizing the Neuropharmacology of Dexmedetomidine Through Trimodal Imaging
The investigators will be studying the sedative drug dexmedetomidine using hybrid PET/fMRI/EEG imaging to better understand the neuropharmacology of anesthesia/artificially induced sleep.
Details
| Lead sponsor | Massachusetts General Hospital |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | UNKNOWN |
| Enrolment | 30 |
| Start date | 2022-04-12 |
| Completion | 2023-04 |
Conditions
- Anesthesia
- Healthy
Interventions
- Dexmedetomidine
- Saline
Primary outcomes
- Brain positron emission tomography (PET) imaging signals. — 2 hours
Changes in dopamine receptor availability will be quantified from brain PET images. - Functional magnetic resonance imaging (fMRI) signals. — 2 hours
fMRI measures of hemodynamic responses. - Differences in electroencephalography (EEG) measures between arousal and anesthesia. — 2 hours
Arousal states will be characterized from changes in the EEG power spectrum.
Countries
United States